https://www.selleckchem.com/pr....oducts/z-devd-fmk.ht
unicable diseases should be emphasized. Metastatic castration-resistant prostate cancer (mCRPC) patients have a poor prognosis, and curcumin is known to have antineoplastic properties. On the basis of previous phase I and phase II studies, we investigated whether the association of curcumin with docetaxel could improve prognosis among mCRPC patients. A total of 50 mCRPC patients (included from June 2014 to July 2016) treated with docetaxel in association with oral curcumin (6g/d for 7days every 3weeks) versus placebo were included in
Curtir
Comentario
Compartilhar
